Table 1.
Baseline characteristics of nasopharyngeal carcinoma patients who underwent chemoradiotherapy with or without cetuximab
| Before propensity score matching | After propensity score matching | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| CCRT+C | CCRT | P | CCRT+C | CCRT | P | |||||
| (N=75) | (N=606) | (N=75) | (N=150) | |||||||
| No. | % | No. | % | No. | % | No. | % | |||
| Age | <0.001 | 0.894 | ||||||||
| Mean | 47.41 | 50.36 | 47.41 | 47.86 | ||||||
| SD | 10.70 | 11.9 | 10.70 | 10.45 | ||||||
| Median | 47.00 | 50.00 | 47.00 | 47.00 | ||||||
| Sex | 0.457 | 0.615 | ||||||||
| Male | 61 | 81.3 | 470 | 77.6 | 61 | 81.3 | 126 | 84.0 | ||
| Female | 14 | 18.7 | 136 | 22.4 | 14 | 18.7 | 24 | 16.0 | ||
| BMI | 0.361 | 0.890 | ||||||||
| Mean | 22.6 | 22.4 | 22.6 | 22.6 | ||||||
| SD | 3.2 | 3.5 | 3.2 | 2.9 | ||||||
| Median | 22.5 | 22.3 | 22.5 | 22.5 | ||||||
| Histologya | 0.089 | 0.380 | ||||||||
| I+II | 1 | 4.0 | 37 | 4.8 | 1 | 4.0 | 5 | 3.3 | ||
| III | 74 | 96.0 | 569 | 95.2 | 74 | 96.0 | 145 | 96.7 | ||
| EA-lgAb | 0.034 | 0.340 | ||||||||
| <10 | 14 | 18.7 | 187 | 30.9 | 9 | 12.0 | 24 | 16.0 | ||
| 10-40 | 25 | 33.3 | 210 | 34.7 | 29 | 38.7 | 44 | 29.3 | ||
| ≥40 | 36 | 48.0 | 209 | 34.5 | 37 | 49.3 | 82 | 54.7 | ||
| VCA-lgAb | 0.090 | 0.709 | ||||||||
| <80 | 10 | 13.3 | 120 | 19.8 | 10 | 13.3 | 25 | 16.7 | ||
| 80-320 | 22 | 29.3 | 218 | 36.0 | 22 | 29.3 | 47 | 31.3 | ||
| ≥320 | 43 | 57.3 | 268 | 44.2 | 43 | 57.3 | 78 | 52.0 | ||
| T-stage | 0.004 | 0.987 | ||||||||
| T1 | 8 | 10.7 | 22 | 3.63 | 8 | 10.7 | 14 | 9.3 | ||
| T2 | 10 | 13.3 | 43 | 7.10 | 10 | 13.3 | 19 | 12.7 | ||
| T3 | 26 | 34.7 | 291 | 48.0 | 26 | 34.7 | 54 | 36.0 | ||
| T4 | 31 | 41.3 | 250 | 41.3 | 31 | 41.3 | 63 | 42.0 | ||
| N-stage | 0.033 | 0.994 | ||||||||
| N0 | 3 | 4.0 | 51 | 8.42 | 3 | 4.0 | 7 | 4.7 | ||
| N1 | 29 | 38.7 | 302 | 49.8 | 29 | 38.7 | 59 | 39.3 | ||
| N2 | 31 | 41.3 | 202 | 33.3 | 31 | 41.3 | 60 | 40.0 | ||
| N3 | 12 | 16.0 | 51 | 8.42 | 12 | 16.0 | 24 | 16.0 | ||
| Clinical stage | 0.085 | 1.000 | ||||||||
| III | 38 | 50.7 | 312 | 51.5 | 38 | 50.7 | 76 | 50.7 | ||
| IVa | 25 | 33.3 | 243 | 40.1 | 25 | 33.3 | 50 | 33.3 | ||
| IVb | 12 | 16.0 | 51 | 8.42 | 12 | 16.0 | 24 | 16.0 | ||
Abbreviations: CCRT = concurrent chemoradiotherapy, C = cetuximab, SD = standard deviation, BMI = body mass index, VCA = viral capsid antigen, lgA = immunoglobulin A, EA = early antigen.
a Based on the criteria of WHO histological type (1991): I - Keratinising squamous-cell carcinoma, II - Differentiated non-keratinising carcinoma, III - Undifferentiated non- keratinising carcinoma.
b In accordance with the criteria adopted in previous studies.
c Used Fisher's exact test.